Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Brain Neoplasms | 49 | 2023 | 4868 | 2.160 |
Why?
|
Spinal Neoplasms | 27 | 2017 | 632 | 1.780 |
Why?
|
Radiosurgery | 11 | 2023 | 1332 | 1.110 |
Why?
|
Glioblastoma | 18 | 2020 | 1810 | 0.930 |
Why?
|
Neurosurgical Procedures | 13 | 2023 | 610 | 0.810 |
Why?
|
Meningeal Neoplasms | 4 | 2023 | 443 | 0.780 |
Why?
|
Craniotomy | 11 | 2021 | 304 | 0.770 |
Why?
|
Glioma | 12 | 2021 | 1971 | 0.590 |
Why?
|
Cerebral Ventricle Neoplasms | 4 | 2023 | 81 | 0.540 |
Why?
|
Tuberculoma, Intracranial | 1 | 2015 | 9 | 0.530 |
Why?
|
Spinal Cord Compression | 6 | 2017 | 151 | 0.500 |
Why?
|
Retrospective Studies | 71 | 2023 | 38006 | 0.460 |
Why?
|
Middle Aged | 102 | 2023 | 86445 | 0.450 |
Why?
|
Neoplasm Metastasis | 4 | 2020 | 5121 | 0.430 |
Why?
|
Central Nervous System | 1 | 2015 | 439 | 0.430 |
Why?
|
Adult | 96 | 2022 | 78087 | 0.420 |
Why?
|
Aged | 90 | 2020 | 70322 | 0.420 |
Why?
|
Treatment Outcome | 57 | 2023 | 32987 | 0.390 |
Why?
|
Magnetic Resonance Imaging | 20 | 2023 | 7727 | 0.380 |
Why?
|
Postoperative Complications | 20 | 2017 | 5565 | 0.370 |
Why?
|
Aged, 80 and over | 51 | 2020 | 29997 | 0.370 |
Why?
|
Supratentorial Neoplasms | 2 | 2013 | 80 | 0.350 |
Why?
|
Adolescent | 51 | 2022 | 31257 | 0.340 |
Why?
|
Male | 96 | 2023 | 123277 | 0.340 |
Why?
|
Female | 99 | 2023 | 142240 | 0.330 |
Why?
|
Thoracic Vertebrae | 3 | 2001 | 188 | 0.330 |
Why?
|
Wakefulness | 4 | 2014 | 150 | 0.320 |
Why?
|
Pia Mater | 1 | 2008 | 14 | 0.320 |
Why?
|
Arachnoid | 1 | 2008 | 14 | 0.320 |
Why?
|
Skull Base Neoplasms | 6 | 2012 | 315 | 0.310 |
Why?
|
Laser Therapy | 3 | 2017 | 411 | 0.310 |
Why?
|
Neoplasm Seeding | 1 | 2008 | 66 | 0.310 |
Why?
|
Neutropenia | 5 | 2000 | 968 | 0.310 |
Why?
|
Humans | 126 | 2023 | 262210 | 0.300 |
Why?
|
Spine | 3 | 2015 | 294 | 0.300 |
Why?
|
Sacrum | 4 | 2012 | 134 | 0.270 |
Why?
|
Diagnosis, Differential | 1 | 2015 | 4756 | 0.270 |
Why?
|
Young Adult | 28 | 2022 | 21474 | 0.260 |
Why?
|
Catheters, Indwelling | 6 | 2013 | 374 | 0.260 |
Why?
|
Monitoring, Intraoperative | 5 | 2014 | 264 | 0.260 |
Why?
|
Cross Infection | 3 | 2001 | 544 | 0.260 |
Why?
|
Drug Therapy, Combination | 5 | 2001 | 2323 | 0.250 |
Why?
|
Stereotaxic Techniques | 4 | 2016 | 172 | 0.250 |
Why?
|
Survival Rate | 22 | 2015 | 12236 | 0.240 |
Why?
|
Neuronavigation | 2 | 2017 | 47 | 0.240 |
Why?
|
Glioma, Subependymal | 1 | 2023 | 25 | 0.230 |
Why?
|
Hyperthermia, Induced | 3 | 2017 | 511 | 0.220 |
Why?
|
Prognosis | 27 | 2015 | 21747 | 0.220 |
Why?
|
Incidence | 12 | 2015 | 5709 | 0.220 |
Why?
|
Orthopedic Procedures | 3 | 2011 | 146 | 0.220 |
Why?
|
Fourth Ventricle | 2 | 2023 | 51 | 0.210 |
Why?
|
Pinealoma | 1 | 2022 | 49 | 0.200 |
Why?
|
Karnofsky Performance Status | 7 | 2015 | 175 | 0.200 |
Why?
|
Multivariate Analysis | 13 | 2015 | 4321 | 0.200 |
Why?
|
Penicillanic Acid | 1 | 2001 | 20 | 0.200 |
Why?
|
Orbit Evisceration | 1 | 2021 | 46 | 0.190 |
Why?
|
Kaplan-Meier Estimate | 11 | 2020 | 6219 | 0.190 |
Why?
|
Mental Status and Dementia Tests | 1 | 2021 | 36 | 0.190 |
Why?
|
Lumbar Vertebrae | 4 | 2005 | 248 | 0.190 |
Why?
|
Radiography | 7 | 2015 | 1912 | 0.190 |
Why?
|
Sarcoma | 5 | 2014 | 1726 | 0.190 |
Why?
|
Meningioma | 1 | 2023 | 290 | 0.180 |
Why?
|
Bone Marrow Transplantation | 4 | 2001 | 1582 | 0.180 |
Why?
|
Diffusion Magnetic Resonance Imaging | 2 | 2020 | 341 | 0.180 |
Why?
|
Pneumonia, Bacterial | 1 | 2001 | 130 | 0.180 |
Why?
|
Survival Analysis | 19 | 2015 | 9186 | 0.170 |
Why?
|
Intraoperative Neurophysiological Monitoring | 1 | 2019 | 32 | 0.170 |
Why?
|
Pyramidal Tracts | 1 | 2019 | 57 | 0.170 |
Why?
|
Opportunistic Infections | 1 | 2001 | 225 | 0.170 |
Why?
|
Imipenem | 3 | 1998 | 23 | 0.170 |
Why?
|
Cranial Fossa, Anterior | 2 | 2010 | 15 | 0.170 |
Why?
|
Connectome | 1 | 2021 | 115 | 0.170 |
Why?
|
Lung Neoplasms | 7 | 2014 | 11573 | 0.170 |
Why?
|
Anti-Bacterial Agents | 7 | 2013 | 2995 | 0.170 |
Why?
|
Hospitals, University | 2 | 2020 | 211 | 0.160 |
Why?
|
Catheterization, Central Venous | 5 | 2000 | 355 | 0.160 |
Why?
|
Pseudomonas Infections | 1 | 2000 | 156 | 0.160 |
Why?
|
Fungemia | 2 | 2000 | 116 | 0.160 |
Why?
|
Child | 22 | 2017 | 29135 | 0.160 |
Why?
|
Prospective Studies | 18 | 2021 | 12914 | 0.160 |
Why?
|
Pseudomonas aeruginosa | 1 | 2000 | 231 | 0.160 |
Why?
|
Ganciclovir | 2 | 1999 | 174 | 0.160 |
Why?
|
Magnetic Resonance Imaging, Interventional | 2 | 2016 | 97 | 0.160 |
Why?
|
Artificial Intelligence | 1 | 2022 | 389 | 0.150 |
Why?
|
SOXB1 Transcription Factors | 2 | 2015 | 124 | 0.150 |
Why?
|
Follow-Up Studies | 18 | 2017 | 14904 | 0.150 |
Why?
|
Risk Factors | 16 | 2015 | 17605 | 0.150 |
Why?
|
Diffusion Tensor Imaging | 1 | 2019 | 305 | 0.150 |
Why?
|
Brain | 5 | 2016 | 4113 | 0.150 |
Why?
|
Cohort Studies | 12 | 2021 | 9293 | 0.140 |
Why?
|
Rifampin | 3 | 1998 | 192 | 0.140 |
Why?
|
Kidney Neoplasms | 4 | 2015 | 3023 | 0.140 |
Why?
|
Nervous System Diseases | 4 | 2017 | 499 | 0.140 |
Why?
|
Child, Preschool | 13 | 2015 | 16256 | 0.140 |
Why?
|
Methylmethacrylate | 2 | 2000 | 15 | 0.140 |
Why?
|
Equipment Contamination | 3 | 1998 | 90 | 0.140 |
Why?
|
Bone Screws | 2 | 2001 | 84 | 0.130 |
Why?
|
Decompression, Surgical | 3 | 2016 | 144 | 0.130 |
Why?
|
Osteosarcoma | 2 | 2014 | 931 | 0.130 |
Why?
|
Texas | 8 | 2020 | 6307 | 0.130 |
Why?
|
Neoplasms | 7 | 2014 | 15204 | 0.130 |
Why?
|
Deep Brain Stimulation | 1 | 2019 | 351 | 0.130 |
Why?
|
Blood Vessel Prosthesis Implantation | 2 | 2014 | 708 | 0.120 |
Why?
|
Cancer Care Facilities | 3 | 2015 | 884 | 0.120 |
Why?
|
Cognition | 1 | 2021 | 975 | 0.120 |
Why?
|
Candidiasis | 2 | 1997 | 262 | 0.120 |
Why?
|
Cytomegalovirus Infections | 2 | 1999 | 453 | 0.120 |
Why?
|
Cervical Vertebrae | 2 | 2000 | 206 | 0.120 |
Why?
|
Predictive Value of Tests | 7 | 2014 | 4902 | 0.120 |
Why?
|
Graft Occlusion, Vascular | 1 | 2014 | 118 | 0.120 |
Why?
|
Glasgow Coma Scale | 1 | 2014 | 215 | 0.120 |
Why?
|
Temporal Lobe | 1 | 2015 | 192 | 0.120 |
Why?
|
Neurosurgery | 2 | 2015 | 108 | 0.110 |
Why?
|
Thrombectomy | 1 | 2014 | 158 | 0.110 |
Why?
|
Wounds, Gunshot | 1 | 2014 | 102 | 0.110 |
Why?
|
Fluconazole | 3 | 2000 | 103 | 0.110 |
Why?
|
Arteriovenous Shunt, Surgical | 1 | 2014 | 112 | 0.110 |
Why?
|
Craniocerebral Trauma | 1 | 2014 | 131 | 0.110 |
Why?
|
Bacterial Infections | 2 | 1998 | 478 | 0.110 |
Why?
|
Astrocytoma | 2 | 2013 | 323 | 0.110 |
Why?
|
Disability Evaluation | 1 | 2014 | 256 | 0.110 |
Why?
|
Oligodendroglioma | 2 | 2011 | 106 | 0.110 |
Why?
|
Phenytoin | 1 | 2013 | 71 | 0.110 |
Why?
|
Intracranial Hemorrhages | 2 | 2014 | 121 | 0.110 |
Why?
|
Antitubercular Agents | 1 | 2015 | 319 | 0.110 |
Why?
|
Antiviral Agents | 3 | 1999 | 1232 | 0.110 |
Why?
|
Breast Neoplasms | 6 | 2020 | 15708 | 0.110 |
Why?
|
Intraoperative Complications | 1 | 2014 | 302 | 0.100 |
Why?
|
Eclampsia | 2 | 1997 | 28 | 0.100 |
Why?
|
Mice, Nude | 4 | 2015 | 4318 | 0.100 |
Why?
|
Carcinoma, Renal Cell | 2 | 2015 | 2327 | 0.100 |
Why?
|
Disease-Free Survival | 8 | 2023 | 10009 | 0.100 |
Why?
|
Registries | 4 | 2014 | 2187 | 0.100 |
Why?
|
Chordoma | 2 | 2006 | 163 | 0.100 |
Why?
|
Melanoma | 4 | 2015 | 5321 | 0.100 |
Why?
|
Catheterization | 1 | 2013 | 410 | 0.100 |
Why?
|
Neuropsychological Tests | 1 | 2015 | 1174 | 0.100 |
Why?
|
Neoplasm Recurrence, Local | 10 | 2023 | 10066 | 0.100 |
Why?
|
Proto-Oncogene Proteins c-sis | 1 | 2011 | 80 | 0.100 |
Why?
|
Back Pain | 2 | 2003 | 62 | 0.090 |
Why?
|
Brain Stem Neoplasms | 1 | 2011 | 108 | 0.090 |
Why?
|
Disease Models, Animal | 3 | 2014 | 7226 | 0.090 |
Why?
|
Cerebrum | 1 | 2010 | 44 | 0.090 |
Why?
|
Extracellular Space | 1 | 2010 | 131 | 0.090 |
Why?
|
Bone Substitutes | 1 | 2000 | 15 | 0.090 |
Why?
|
Catheter-Related Infections | 1 | 2013 | 269 | 0.090 |
Why?
|
Third Ventricle | 1 | 2010 | 37 | 0.090 |
Why?
|
Pain Measurement | 5 | 2015 | 983 | 0.090 |
Why?
|
Cerebral Ventricles | 1 | 2010 | 98 | 0.090 |
Why?
|
Cognition Disorders | 1 | 2015 | 786 | 0.090 |
Why?
|
Neoplasms, Unknown Primary | 1 | 2011 | 192 | 0.090 |
Why?
|
Seizures | 2 | 2013 | 989 | 0.090 |
Why?
|
Isocitrate Dehydrogenase | 1 | 2013 | 482 | 0.090 |
Why?
|
Amphotericin B | 2 | 2000 | 289 | 0.090 |
Why?
|
Corpus Callosum | 1 | 2010 | 138 | 0.090 |
Why?
|
Anticonvulsants | 1 | 2013 | 431 | 0.090 |
Why?
|
Receptors, Progesterone | 1 | 2015 | 1388 | 0.090 |
Why?
|
Motor Cortex | 1 | 2010 | 118 | 0.090 |
Why?
|
Schools, Medical | 1 | 2010 | 132 | 0.090 |
Why?
|
Clinical Clerkship | 1 | 2010 | 104 | 0.080 |
Why?
|
Radiotherapy | 3 | 2010 | 1826 | 0.080 |
Why?
|
Cerebral Cortex | 2 | 2013 | 624 | 0.080 |
Why?
|
Mycobacterium fortuitum | 1 | 1998 | 2 | 0.080 |
Why?
|
Proportional Hazards Models | 6 | 2020 | 5008 | 0.080 |
Why?
|
Mycobacterium chelonae | 1 | 1998 | 6 | 0.080 |
Why?
|
Skull | 1 | 2010 | 231 | 0.080 |
Why?
|
Cilastatin | 1 | 1998 | 2 | 0.080 |
Why?
|
Prosthesis Implantation | 1 | 2011 | 265 | 0.080 |
Why?
|
Logistic Models | 7 | 2014 | 3450 | 0.080 |
Why?
|
Skull Base | 2 | 2007 | 200 | 0.080 |
Why?
|
Perioperative Care | 1 | 2013 | 453 | 0.080 |
Why?
|
Glutamic Acid | 1 | 2010 | 309 | 0.080 |
Why?
|
Hemifacial Spasm | 1 | 2008 | 21 | 0.080 |
Why?
|
Orthopedic Fixation Devices | 2 | 2003 | 20 | 0.080 |
Why?
|
Thienamycins | 1 | 1998 | 23 | 0.080 |
Why?
|
Referral and Consultation | 1 | 2014 | 899 | 0.080 |
Why?
|
Infection Control | 2 | 1998 | 270 | 0.080 |
Why?
|
Decision Support Techniques | 1 | 2014 | 623 | 0.080 |
Why?
|
Wound Infection | 1 | 1999 | 54 | 0.080 |
Why?
|
Thromboplastin | 1 | 2008 | 34 | 0.080 |
Why?
|
Infusions, Intra-Arterial | 1 | 1998 | 177 | 0.080 |
Why?
|
Novobiocin | 1 | 1998 | 8 | 0.080 |
Why?
|
Nursing Staff, Hospital | 1 | 1999 | 69 | 0.080 |
Why?
|
Infant | 5 | 2014 | 13299 | 0.080 |
Why?
|
Neoplasms, Radiation-Induced | 1 | 2010 | 389 | 0.080 |
Why?
|
Cranial Fossa, Posterior | 1 | 2008 | 49 | 0.080 |
Why?
|
Pons | 1 | 2008 | 51 | 0.080 |
Why?
|
Immunocompromised Host | 2 | 2003 | 697 | 0.080 |
Why?
|
Antineoplastic Agents, Alkylating | 1 | 2001 | 588 | 0.080 |
Why?
|
Facial Bones | 1 | 2007 | 40 | 0.080 |
Why?
|
Mycobacterium Infections, Nontuberculous | 1 | 1998 | 82 | 0.080 |
Why?
|
Antibiotics, Antitubercular | 2 | 1998 | 38 | 0.080 |
Why?
|
Vancomycin | 2 | 1996 | 274 | 0.080 |
Why?
|
ErbB Receptors | 2 | 2007 | 2296 | 0.080 |
Why?
|
Transplantation, Homologous | 2 | 2001 | 2844 | 0.080 |
Why?
|
Receptors, Estrogen | 1 | 2015 | 2085 | 0.080 |
Why?
|
p21-Activated Kinases | 1 | 2007 | 124 | 0.070 |
Why?
|
Electric Stimulation | 3 | 2014 | 427 | 0.070 |
Why?
|
Protease Inhibitors | 1 | 1998 | 210 | 0.070 |
Why?
|
Cefoperazone | 1 | 1996 | 7 | 0.070 |
Why?
|
Sulbactam | 1 | 1996 | 8 | 0.070 |
Why?
|
Renal Dialysis | 1 | 2014 | 949 | 0.070 |
Why?
|
Language | 1 | 2009 | 311 | 0.070 |
Why?
|
Fever | 2 | 1998 | 497 | 0.070 |
Why?
|
Chondrosarcoma | 1 | 1999 | 216 | 0.070 |
Why?
|
Antineoplastic Agents | 6 | 2010 | 14301 | 0.070 |
Why?
|
Combined Modality Therapy | 8 | 2015 | 8883 | 0.070 |
Why?
|
Virus Diseases | 1 | 2000 | 399 | 0.070 |
Why?
|
Confidence Intervals | 4 | 2010 | 756 | 0.070 |
Why?
|
Microsurgery | 1 | 2008 | 244 | 0.070 |
Why?
|
Kidney Failure, Chronic | 1 | 2014 | 969 | 0.070 |
Why?
|
Minocycline | 2 | 1998 | 182 | 0.070 |
Why?
|
Radiotherapy, Adjuvant | 3 | 2023 | 2233 | 0.070 |
Why?
|
Aztreonam | 2 | 2001 | 14 | 0.070 |
Why?
|
Candida | 1 | 1997 | 165 | 0.070 |
Why?
|
Walking | 3 | 2009 | 277 | 0.070 |
Why?
|
Antibodies, Neoplasm | 1 | 2006 | 258 | 0.060 |
Why?
|
Age Distribution | 4 | 2009 | 704 | 0.060 |
Why?
|
Receptor, ErbB-2 | 1 | 2015 | 2518 | 0.060 |
Why?
|
Chitinase-3-Like Protein 1 | 3 | 2012 | 18 | 0.060 |
Why?
|
Antigen-Presenting Cells | 1 | 2006 | 284 | 0.060 |
Why?
|
Bone Plates | 2 | 2000 | 47 | 0.060 |
Why?
|
Memory | 2 | 2021 | 429 | 0.060 |
Why?
|
Palliative Care | 2 | 2015 | 2035 | 0.060 |
Why?
|
Microglia | 1 | 2006 | 166 | 0.060 |
Why?
|
Databases as Topic | 1 | 2005 | 134 | 0.060 |
Why?
|
Necrosis | 2 | 2008 | 585 | 0.060 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 1 | 2011 | 1494 | 0.060 |
Why?
|
Antifungal Agents | 1 | 2000 | 840 | 0.060 |
Why?
|
Lectins | 3 | 2012 | 151 | 0.060 |
Why?
|
Thyroid Neoplasms | 1 | 2015 | 1867 | 0.060 |
Why?
|
Interleukin-2 | 1 | 1998 | 839 | 0.060 |
Why?
|
Adipokines | 3 | 2012 | 96 | 0.060 |
Why?
|
Postoperative Period | 3 | 2009 | 667 | 0.060 |
Why?
|
Facial Neoplasms | 1 | 2004 | 84 | 0.060 |
Why?
|
Repressor Proteins | 1 | 2012 | 1662 | 0.060 |
Why?
|
Brain Injuries | 1 | 2010 | 790 | 0.060 |
Why?
|
Cytomegalovirus | 1 | 1997 | 475 | 0.060 |
Why?
|
Neoplastic Stem Cells | 1 | 2012 | 1447 | 0.060 |
Why?
|
Mitogen-Activated Protein Kinases | 1 | 2006 | 640 | 0.060 |
Why?
|
Parainfluenza Virus 1, Human | 1 | 2003 | 5 | 0.060 |
Why?
|
Patient Care Team | 1 | 1999 | 799 | 0.060 |
Why?
|
Time Factors | 8 | 2014 | 12967 | 0.060 |
Why?
|
Chi-Square Distribution | 2 | 2009 | 1329 | 0.060 |
Why?
|
Respirovirus Infections | 1 | 2003 | 36 | 0.060 |
Why?
|
Cerebellar Neoplasms | 1 | 2008 | 434 | 0.060 |
Why?
|
Disease Progression | 6 | 2015 | 6695 | 0.060 |
Why?
|
Respiratory Syncytial Virus Infections | 1 | 1997 | 427 | 0.060 |
Why?
|
Atlanto-Axial Joint | 1 | 2003 | 25 | 0.060 |
Why?
|
Kyphosis | 2 | 2003 | 43 | 0.050 |
Why?
|
Bone Cements | 2 | 2003 | 45 | 0.050 |
Why?
|
Leukemia | 2 | 2003 | 1632 | 0.050 |
Why?
|
Lung Diseases | 1 | 1998 | 717 | 0.050 |
Why?
|
Intestinal Neoplasms | 1 | 2004 | 189 | 0.050 |
Why?
|
Patient Selection | 2 | 2014 | 2059 | 0.050 |
Why?
|
Carcinoid Tumor | 1 | 2004 | 280 | 0.050 |
Why?
|
Awards and Prizes | 1 | 2004 | 98 | 0.050 |
Why?
|
Respiratory Tract Diseases | 1 | 2003 | 111 | 0.050 |
Why?
|
Transplantation Conditioning | 1 | 2001 | 2238 | 0.050 |
Why?
|
Recovery of Function | 3 | 2015 | 718 | 0.050 |
Why?
|
Sex Distribution | 3 | 2009 | 497 | 0.050 |
Why?
|
Neoplasms, Second Primary | 1 | 2010 | 1351 | 0.050 |
Why?
|
Hematologic Neoplasms | 2 | 2000 | 1870 | 0.050 |
Why?
|
MicroRNAs | 1 | 2015 | 2955 | 0.050 |
Why?
|
Phosphoproteins | 1 | 2007 | 1151 | 0.050 |
Why?
|
Data Accuracy | 1 | 2022 | 54 | 0.050 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 2 | 2009 | 5339 | 0.050 |
Why?
|
Spinal Fractures | 1 | 2003 | 132 | 0.050 |
Why?
|
Piperacillin | 1 | 2001 | 29 | 0.050 |
Why?
|
Microbial Sensitivity Tests | 2 | 2000 | 997 | 0.050 |
Why?
|
NF-kappa B | 1 | 2008 | 1551 | 0.050 |
Why?
|
Amikacin | 1 | 2001 | 34 | 0.050 |
Why?
|
Clindamycin | 1 | 2001 | 50 | 0.050 |
Why?
|
Carcinoma, Endometrioid | 1 | 2004 | 324 | 0.050 |
Why?
|
Intestine, Small | 1 | 2004 | 499 | 0.050 |
Why?
|
Biomarkers, Tumor | 3 | 2015 | 10356 | 0.050 |
Why?
|
Carcinoma, Adenoid Cystic | 1 | 2004 | 421 | 0.050 |
Why?
|
Risk | 3 | 2016 | 1972 | 0.050 |
Why?
|
Adenocarcinoma, Mucinous | 1 | 2004 | 436 | 0.050 |
Why?
|
Stroke | 1 | 2009 | 1155 | 0.050 |
Why?
|
Nervous System | 2 | 2001 | 165 | 0.050 |
Why?
|
Postoperative Care | 2 | 2017 | 738 | 0.050 |
Why?
|
Carcinoma, Papillary | 1 | 2004 | 584 | 0.040 |
Why?
|
Lactams | 1 | 2000 | 24 | 0.040 |
Why?
|
Macrophages | 1 | 2006 | 1300 | 0.040 |
Why?
|
Executive Function | 1 | 2021 | 159 | 0.040 |
Why?
|
Ophthalmologic Surgical Procedures | 1 | 2001 | 177 | 0.040 |
Why?
|
Cystadenocarcinoma, Serous | 1 | 2004 | 487 | 0.040 |
Why?
|
Methylmethacrylates | 1 | 1998 | 16 | 0.040 |
Why?
|
Orbital Neoplasms | 1 | 2001 | 225 | 0.040 |
Why?
|
Internship and Residency | 1 | 2010 | 1410 | 0.040 |
Why?
|
Neoplasm, Residual | 2 | 2015 | 1668 | 0.040 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2006 | 2062 | 0.040 |
Why?
|
Pulmonary Atelectasis | 1 | 1998 | 46 | 0.040 |
Why?
|
Brain Mapping | 2 | 2014 | 646 | 0.040 |
Why?
|
Adenocarcinoma | 2 | 2009 | 7792 | 0.040 |
Why?
|
Myelodysplastic Syndromes | 1 | 2001 | 2979 | 0.040 |
Why?
|
Gene Expression Regulation, Neoplastic | 3 | 2015 | 8891 | 0.040 |
Why?
|
Reproducibility of Results | 3 | 2014 | 6036 | 0.040 |
Why?
|
Sepsis | 2 | 1999 | 655 | 0.040 |
Why?
|
Nerve Net | 1 | 2021 | 257 | 0.040 |
Why?
|
Cranial Irradiation | 3 | 2004 | 316 | 0.040 |
Why?
|
Neoplasm Grading | 2 | 2013 | 1748 | 0.040 |
Why?
|
Muscle Weakness | 1 | 1998 | 116 | 0.040 |
Why?
|
Cranial Nerve Injuries | 1 | 2017 | 9 | 0.040 |
Why?
|
Tocolytic Agents | 1 | 1997 | 7 | 0.040 |
Why?
|
Odds Ratio | 3 | 2010 | 2326 | 0.040 |
Why?
|
Neoplasm Transplantation | 2 | 2012 | 1518 | 0.040 |
Why?
|
Ventriculostomy | 1 | 2017 | 34 | 0.040 |
Why?
|
Magnesium Sulfate | 1 | 1997 | 39 | 0.040 |
Why?
|
Cell Line, Tumor | 5 | 2014 | 14590 | 0.040 |
Why?
|
Pain, Intractable | 1 | 1998 | 171 | 0.040 |
Why?
|
Gait Disorders, Neurologic | 1 | 2017 | 58 | 0.040 |
Why?
|
Cerebrospinal Fluid Shunts | 1 | 2017 | 72 | 0.040 |
Why?
|
Speech Disorders | 1 | 2017 | 91 | 0.040 |
Why?
|
Biomedical Research | 1 | 2004 | 807 | 0.030 |
Why?
|
Fluoroscopy | 1 | 2017 | 232 | 0.030 |
Why?
|
Pain, Postoperative | 2 | 2015 | 619 | 0.030 |
Why?
|
Chemotherapy, Adjuvant | 3 | 2010 | 3891 | 0.030 |
Why?
|
Case-Control Studies | 4 | 2005 | 6105 | 0.030 |
Why?
|
Hematopoietic Stem Cell Transplantation | 2 | 2001 | 6560 | 0.030 |
Why?
|
Anesthesia, General | 1 | 2017 | 239 | 0.030 |
Why?
|
Patient Positioning | 1 | 2017 | 195 | 0.030 |
Why?
|
Immunohistochemistry | 4 | 2008 | 7558 | 0.030 |
Why?
|
Pulmonary Embolism | 1 | 1998 | 329 | 0.030 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2022 | 1651 | 0.030 |
Why?
|
Adie Syndrome | 1 | 2014 | 4 | 0.030 |
Why?
|
Photomicrography | 1 | 2014 | 26 | 0.030 |
Why?
|
Acute Disease | 1 | 2000 | 2424 | 0.030 |
Why?
|
Risk Assessment | 3 | 2015 | 6891 | 0.030 |
Why?
|
Probability | 2 | 2009 | 868 | 0.030 |
Why?
|
Immunosuppressive Agents | 2 | 2001 | 1384 | 0.030 |
Why?
|
Pre-Eclampsia | 1 | 1997 | 210 | 0.030 |
Why?
|
Ohio | 1 | 2014 | 113 | 0.030 |
Why?
|
Nonlinear Dynamics | 1 | 2014 | 78 | 0.030 |
Why?
|
Luminescent Measurements | 1 | 2014 | 148 | 0.030 |
Why?
|
Algorithms | 2 | 2020 | 3891 | 0.030 |
Why?
|
Mutation | 1 | 2013 | 15194 | 0.030 |
Why?
|
Vascular Patency | 1 | 2014 | 218 | 0.030 |
Why?
|
Preoperative Period | 1 | 2014 | 344 | 0.030 |
Why?
|
Lymph Nodes | 1 | 2004 | 2969 | 0.030 |
Why?
|
Biopsy | 1 | 2001 | 3457 | 0.030 |
Why?
|
Meningitis | 1 | 2013 | 112 | 0.030 |
Why?
|
Glycoproteins | 2 | 2007 | 748 | 0.030 |
Why?
|
Intracranial Hypertension | 1 | 2014 | 119 | 0.030 |
Why?
|
Memory Disorders | 1 | 2015 | 295 | 0.030 |
Why?
|
Sensitivity and Specificity | 1 | 2001 | 4977 | 0.030 |
Why?
|
Analysis of Variance | 2 | 2009 | 2311 | 0.030 |
Why?
|
Treatment Failure | 2 | 2005 | 1392 | 0.030 |
Why?
|
Prostatic Neoplasms | 1 | 2009 | 5777 | 0.030 |
Why?
|
Carcinoma | 1 | 2003 | 2583 | 0.030 |
Why?
|
Quality of Life | 2 | 2016 | 4577 | 0.030 |
Why?
|
Heterografts | 1 | 2014 | 734 | 0.030 |
Why?
|
Medical Oncology | 1 | 2020 | 1425 | 0.030 |
Why?
|
DNA-Binding Proteins | 1 | 2005 | 4794 | 0.030 |
Why?
|
Anemia, Refractory, with Excess of Blasts | 1 | 2001 | 86 | 0.030 |
Why?
|
Leukemia, Myeloid, Acute | 1 | 2001 | 6915 | 0.030 |
Why?
|
Thiotepa | 1 | 2001 | 118 | 0.020 |
Why?
|
Imaging, Three-Dimensional | 1 | 2016 | 927 | 0.020 |
Why?
|
Blood Vessel Prosthesis | 1 | 2014 | 415 | 0.020 |
Why?
|
Feasibility Studies | 1 | 2017 | 2300 | 0.020 |
Why?
|
Multiple Myeloma | 1 | 2003 | 2150 | 0.020 |
Why?
|
Spheroids, Cellular | 1 | 2012 | 222 | 0.020 |
Why?
|
Chemoradiotherapy, Adjuvant | 1 | 2014 | 565 | 0.020 |
Why?
|
Mice | 4 | 2015 | 34438 | 0.020 |
Why?
|
Motor Skills Disorders | 1 | 2010 | 20 | 0.020 |
Why?
|
Animals | 5 | 2015 | 59534 | 0.020 |
Why?
|
Microdialysis | 1 | 2010 | 50 | 0.020 |
Why?
|
Transcription Factors | 1 | 2005 | 5258 | 0.020 |
Why?
|
Chickens | 1 | 2011 | 528 | 0.020 |
Why?
|
Evoked Potentials, Motor | 1 | 2010 | 58 | 0.020 |
Why?
|
Embolization, Therapeutic | 1 | 2015 | 553 | 0.020 |
Why?
|
Vascular Endothelial Growth Factor A | 2 | 2008 | 1536 | 0.020 |
Why?
|
Radiation Dosage | 1 | 2015 | 1016 | 0.020 |
Why?
|
Drug Resistance, Microbial | 1 | 2000 | 217 | 0.020 |
Why?
|
Esophageal Neoplasms | 1 | 2003 | 3170 | 0.020 |
Why?
|
Severity of Illness Index | 2 | 2010 | 4348 | 0.020 |
Why?
|
Spinal Canal | 1 | 2009 | 15 | 0.020 |
Why?
|
Pain | 2 | 2005 | 1675 | 0.020 |
Why?
|
Surgical Instruments | 1 | 2000 | 138 | 0.020 |
Why?
|
Candida albicans | 1 | 2000 | 176 | 0.020 |
Why?
|
Intracranial Pressure | 1 | 2010 | 180 | 0.020 |
Why?
|
Asepsis | 1 | 1999 | 5 | 0.020 |
Why?
|
Reoperation | 2 | 2005 | 1405 | 0.020 |
Why?
|
Tomography, X-Ray Computed | 3 | 2014 | 7573 | 0.020 |
Why?
|
Gene Knockdown Techniques | 1 | 2012 | 1079 | 0.020 |
Why?
|
Neoplasm Invasiveness | 2 | 2007 | 3987 | 0.020 |
Why?
|
Evoked Potentials, Auditory, Brain Stem | 1 | 2008 | 31 | 0.020 |
Why?
|
Morbidity | 1 | 2010 | 401 | 0.020 |
Why?
|
Phosphorylation | 2 | 2007 | 4813 | 0.020 |
Why?
|
Analgesics, Opioid | 1 | 1998 | 1372 | 0.020 |
Why?
|
Bandages | 1 | 1999 | 71 | 0.020 |
Why?
|
Neurologic Examination | 1 | 2009 | 245 | 0.020 |
Why?
|
Shock, Septic | 1 | 2000 | 181 | 0.020 |
Why?
|
Cell Proliferation | 2 | 2012 | 7245 | 0.020 |
Why?
|
Narcotics | 1 | 2009 | 123 | 0.020 |
Why?
|
Spinal Fusion | 1 | 2000 | 149 | 0.020 |
Why?
|
Colony Count, Microbial | 1 | 1998 | 149 | 0.020 |
Why?
|
NF-KappaB Inhibitor alpha | 1 | 2008 | 136 | 0.020 |
Why?
|
Lymphocyte Depletion | 1 | 1999 | 264 | 0.020 |
Why?
|
Facial Nerve | 1 | 2008 | 64 | 0.020 |
Why?
|
Length of Stay | 1 | 2015 | 1929 | 0.020 |
Why?
|
Bayes Theorem | 1 | 2013 | 1032 | 0.020 |
Why?
|
Urinary Incontinence | 1 | 2009 | 148 | 0.020 |
Why?
|
Mentors | 1 | 2010 | 203 | 0.020 |
Why?
|
I-kappa B Proteins | 1 | 2008 | 170 | 0.020 |
Why?
|
Ovarian Neoplasms | 1 | 2004 | 4660 | 0.020 |
Why?
|
Stents | 1 | 2014 | 1099 | 0.020 |
Why?
|
Visitors to Patients | 1 | 1997 | 9 | 0.020 |
Why?
|
Protective Devices | 1 | 1997 | 21 | 0.020 |
Why?
|
Hand Disinfection | 1 | 1997 | 19 | 0.020 |
Why?
|
Patient Isolation | 1 | 1997 | 25 | 0.020 |
Why?
|
Data Collection | 1 | 2010 | 626 | 0.020 |
Why?
|
RNA Interference | 1 | 2012 | 1411 | 0.020 |
Why?
|
Steroids | 1 | 2009 | 356 | 0.020 |
Why?
|
Medical Records | 1 | 1999 | 414 | 0.020 |
Why?
|
Busulfan | 1 | 2001 | 764 | 0.020 |
Why?
|
Faculty, Medical | 1 | 2010 | 299 | 0.020 |
Why?
|
Cells, Cultured | 1 | 2015 | 5606 | 0.020 |
Why?
|
Inservice Training | 1 | 1997 | 77 | 0.020 |
Why?
|
Reference Values | 1 | 2009 | 1098 | 0.020 |
Why?
|
Antibody-Producing Cells | 1 | 2006 | 15 | 0.020 |
Why?
|
Academic Medical Centers | 1 | 2000 | 673 | 0.020 |
Why?
|
Chemoprevention | 1 | 1998 | 242 | 0.020 |
Why?
|
Ribavirin | 1 | 1997 | 178 | 0.020 |
Why?
|
Cross-Over Studies | 1 | 1998 | 462 | 0.020 |
Why?
|
Graft Survival | 1 | 2000 | 1065 | 0.020 |
Why?
|
Mice, Inbred BALB C | 1 | 2011 | 2322 | 0.020 |
Why?
|
Precision Medicine | 1 | 2014 | 1158 | 0.020 |
Why?
|
Oxygen | 1 | 2010 | 754 | 0.020 |
Why?
|
Vomiting | 1 | 1998 | 354 | 0.020 |
Why?
|
Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2006 | 131 | 0.020 |
Why?
|
Interleukin-8 | 1 | 2008 | 520 | 0.020 |
Why?
|
Gram-Positive Bacteria | 1 | 1996 | 66 | 0.020 |
Why?
|
Catheterization, Peripheral | 1 | 1998 | 158 | 0.020 |
Why?
|
Nausea | 1 | 1998 | 525 | 0.020 |
Why?
|
Demography | 1 | 2007 | 437 | 0.020 |
Why?
|
Gram-Negative Bacteria | 1 | 1996 | 100 | 0.020 |
Why?
|
Cytoplasm | 1 | 2007 | 650 | 0.020 |
Why?
|
Parity | 1 | 1995 | 138 | 0.020 |
Why?
|
CD146 Antigen | 1 | 2005 | 57 | 0.020 |
Why?
|
Neural Cell Adhesion Molecules | 1 | 2005 | 55 | 0.020 |
Why?
|
Antigens, Viral | 1 | 1997 | 467 | 0.020 |
Why?
|
Maternal Age | 1 | 1995 | 149 | 0.020 |
Why?
|
Likelihood Functions | 1 | 1995 | 233 | 0.020 |
Why?
|
Transcription Factor AP-2 | 1 | 2005 | 78 | 0.020 |
Why?
|
Leukocyte Count | 1 | 1996 | 684 | 0.020 |
Why?
|
Age Factors | 1 | 2014 | 5386 | 0.020 |
Why?
|
Students, Medical | 1 | 2010 | 418 | 0.020 |
Why?
|
Jejunal Neoplasms | 1 | 2004 | 34 | 0.020 |
Why?
|
Abortion, Induced | 1 | 1995 | 92 | 0.020 |
Why?
|
Ileal Neoplasms | 1 | 2004 | 47 | 0.020 |
Why?
|
Tumor Cells, Cultured | 1 | 2012 | 5387 | 0.020 |
Why?
|
Preoperative Care | 1 | 2001 | 1529 | 0.020 |
Why?
|
Longitudinal Studies | 1 | 2010 | 1949 | 0.020 |
Why?
|
Cyclophosphamide | 1 | 2001 | 3002 | 0.020 |
Why?
|
Abortion, Spontaneous | 1 | 1995 | 112 | 0.010 |
Why?
|
Cell Movement | 1 | 2012 | 2465 | 0.010 |
Why?
|
Amino Acid Motifs | 1 | 2005 | 394 | 0.010 |
Why?
|
Matrix Metalloproteinase 2 | 1 | 2005 | 256 | 0.010 |
Why?
|
Immunologic Factors | 1 | 1998 | 653 | 0.010 |
Why?
|
Administration, Oral | 1 | 1998 | 1556 | 0.010 |
Why?
|
Regression Analysis | 1 | 2007 | 1550 | 0.010 |
Why?
|
Interferon-gamma | 1 | 1998 | 1143 | 0.010 |
Why?
|
Duodenal Neoplasms | 1 | 2004 | 138 | 0.010 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2005 | 521 | 0.010 |
Why?
|
Tumor Burden | 1 | 2009 | 1992 | 0.010 |
Why?
|
Mice, Transgenic | 1 | 2011 | 4140 | 0.010 |
Why?
|
Cell Line | 1 | 2011 | 5088 | 0.010 |
Why?
|
Transfection | 1 | 2008 | 2935 | 0.010 |
Why?
|
Proto-Oncogene Proteins c-kit | 1 | 2005 | 481 | 0.010 |
Why?
|
Gene Expression | 1 | 2011 | 3564 | 0.010 |
Why?
|
Urinary Bladder | 1 | 2005 | 576 | 0.010 |
Why?
|
Fractures, Spontaneous | 1 | 2003 | 84 | 0.010 |
Why?
|
Protein Kinases | 1 | 2006 | 875 | 0.010 |
Why?
|
Bacteremia | 1 | 1998 | 689 | 0.010 |
Why?
|
Body Height | 1 | 2003 | 231 | 0.010 |
Why?
|
Neutrophils | 1 | 1996 | 834 | 0.010 |
Why?
|
RNA, Small Interfering | 1 | 2007 | 2214 | 0.010 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 1 | 2011 | 2373 | 0.010 |
Why?
|
Urinary Tract Infections | 1 | 1995 | 324 | 0.010 |
Why?
|
Intestines | 1 | 2005 | 688 | 0.010 |
Why?
|
Statistics, Nonparametric | 1 | 2003 | 980 | 0.010 |
Why?
|
Biopsy, Needle | 1 | 2004 | 1364 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2011 | 6916 | 0.010 |
Why?
|
Dose-Response Relationship, Drug | 1 | 1998 | 4943 | 0.010 |
Why?
|
Orbit | 1 | 2001 | 206 | 0.010 |
Why?
|
Gene Expression Profiling | 1 | 2012 | 5157 | 0.010 |
Why?
|
Antigens, CD | 1 | 2005 | 1382 | 0.010 |
Why?
|
TOR Serine-Threonine Kinases | 1 | 2006 | 1546 | 0.010 |
Why?
|
Oncology Service, Hospital | 1 | 1999 | 48 | 0.010 |
Why?
|
Pregnancy | 2 | 1997 | 7547 | 0.010 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2005 | 2504 | 0.010 |
Why?
|
Drug Stability | 1 | 1998 | 106 | 0.010 |
Why?
|
Microscopy, Electron, Scanning | 1 | 1998 | 219 | 0.010 |
Why?
|
Electrophoresis, Gel, Pulsed-Field | 1 | 1997 | 128 | 0.010 |
Why?
|
Apoptosis | 1 | 2012 | 7607 | 0.010 |
Why?
|
Lung | 1 | 1998 | 3157 | 0.010 |
Why?
|
Evaluation Studies as Topic | 1 | 1997 | 418 | 0.010 |
Why?
|
Bias | 1 | 1997 | 206 | 0.010 |
Why?
|
Comorbidity | 1 | 2003 | 2394 | 0.010 |
Why?
|
Cell Cycle Proteins | 1 | 2005 | 2054 | 0.010 |
Why?
|
Cause of Death | 1 | 1999 | 755 | 0.010 |
Why?
|
DNA, Bacterial | 1 | 1997 | 557 | 0.010 |
Why?
|
DNA, Viral | 1 | 1997 | 674 | 0.010 |
Why?
|
Recurrence | 1 | 2003 | 4764 | 0.010 |
Why?
|
Clinical Trials as Topic | 1 | 2005 | 3752 | 0.010 |
Why?
|
Cost-Benefit Analysis | 1 | 1997 | 948 | 0.010 |
Why?
|
United States | 1 | 2010 | 15561 | 0.010 |
Why?
|
Obesity | 1 | 1995 | 2893 | 0.010 |
Why?
|
Double-Blind Method | 1 | 1997 | 2598 | 0.010 |
Why?
|
Neoplasm Staging | 1 | 2004 | 13672 | 0.010 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 1997 | 2632 | 0.010 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2004 | 5436 | 0.010 |
Why?
|
Signal Transduction | 1 | 2006 | 11978 | 0.000 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 1998 | 15874 | 0.000 |
Why?
|